In the current study, a significant difference of ACE2 expression was found in responders rather than non-responders to anti-TNFα in IBD patients with colonic involvement, which was validated with IHC assays of CD patients in China cohort (Figure 2A). This evidence concerns the gene ACE2 and inflammatory bowel disease.